On October 14, 2024, the FDA approved a 320-mg single dose of bimekizumab-bkzx (Bimzelx; UCB) in a 2-mL prefilled syringe and autoinjector; both forms are now commercially available in the US.

Breyanzi is a cancer drug, Sotyktu treats psoriasis and Camzyos treats a heart condition. Leerink Partners analyst David ...

Bristol-Myers Squibb (NYSE:BMY) reported its fourth-quarter 2024 earnings, surpassing analyst expectations with an earnings ...